Christopher Navas

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

D. Logan, S. Dillon, M. Maurer, 2022, Nature Communications.

232 Increased potency and functional persistencein vitroof a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology

S. Potluri, A. Hamilton, P. Sundar, 2022, Regular and Young Investigator Award Abstracts.

Large-scale, saturating insertional mutagenesis of the mouse genome

Hongkui Zeng, L. Madisen, Amanda J. Ebbert, 2007, Proceedings of the National Academy of Sciences.